Shengjun Fu

553 total citations
36 papers, 388 citations indexed

About

Shengjun Fu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shengjun Fu has authored 36 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Shengjun Fu's work include Renal and related cancers (6 papers), Cancer Research and Treatments (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Shengjun Fu is often cited by papers focused on Renal and related cancers (6 papers), Cancer Research and Treatments (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Shengjun Fu collaborates with scholars based in China, United States and Norway. Shengjun Fu's co-authors include You Luo, Hu Xiong, Zhiping Wang, Li Yang, Li Yang, Jianzhong Lu, Yongqian Li, Jirong Wang, Qiusheng Zheng and Xuan Yuan and has published in prestigious journals such as PLoS ONE, Chemical Communications and The FASEB Journal.

In The Last Decade

Shengjun Fu

34 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shengjun Fu China 12 117 116 105 98 89 36 388
Jun Qian China 14 110 0.9× 185 1.6× 107 1.0× 90 0.9× 79 0.9× 39 508
Dongdong Lin China 12 179 1.5× 124 1.1× 69 0.7× 102 1.0× 107 1.2× 43 512
Jianrong Guo China 13 202 1.7× 93 0.8× 88 0.8× 81 0.8× 98 1.1× 23 496
Shengbin Dai China 12 291 2.5× 96 0.8× 91 0.9× 77 0.8× 118 1.3× 28 490
Tung‐Cheng Chang Taiwan 12 168 1.4× 221 1.9× 66 0.6× 120 1.2× 88 1.0× 34 449
Zhi Zheng China 13 221 1.9× 84 0.7× 123 1.2× 101 1.0× 97 1.1× 63 491
Sakkarn Sangkhamanon Thailand 13 169 1.4× 144 1.2× 61 0.6× 177 1.8× 88 1.0× 36 419
An-Kui Yang China 16 151 1.3× 299 2.6× 85 0.8× 213 2.2× 56 0.6× 27 664
Jingjing Shao China 11 155 1.3× 111 1.0× 73 0.7× 48 0.5× 52 0.6× 36 366

Countries citing papers authored by Shengjun Fu

Since Specialization
Citations

This map shows the geographic impact of Shengjun Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjun Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjun Fu more than expected).

Fields of papers citing papers by Shengjun Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengjun Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjun Fu. The network helps show where Shengjun Fu may publish in the future.

Co-authorship network of co-authors of Shengjun Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Shengjun Fu. A scholar is included among the top collaborators of Shengjun Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengjun Fu. Shengjun Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gong, Yuwen, Hui Cheng, Junqiang Tian, et al.. (2025). SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway. Communications Biology. 8(1). 36–36. 4 indexed citations
2.
Li, Lanlan, Shengjun Fu, Wenyan Li, et al.. (2025). Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4. Chinese Medicine. 20(1). 71–71.
3.
Wang, Huabin, Hailong Wang, Jiangwei Man, et al.. (2025). Schisandrin B regulates mitochondrial dynamics via AKT1 activation and mitochondrial targeting to ameliorate renal ischemia-reperfusion injury. Phytomedicine. 141. 156672–156672. 1 indexed citations
4.
Li, Xiaoran, Jirong Wang, Kunpeng Li, et al.. (2025). BIN1 inhibited tumor growth, metastasis and stemness by ALDH1/NOTCH pathway in bladder carcinoma. Hereditas. 162(1). 29–29. 1 indexed citations
5.
Wang, Fang, Shengjun Fu, Junqiang Tian, et al.. (2024). Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production. Cell Death and Disease. 15(9). 688–688. 8 indexed citations
6.
Yan, Tao, Shan Wu, Jia‐Wei Lin, et al.. (2024). Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer. Chinese Medicine. 19(1). 7–7. 17 indexed citations
7.
Li, Lanlan, Shengjun Fu, Jianzhong Lu, et al.. (2024). SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux. Biochemical Pharmacology. 222. 116111–116111. 4 indexed citations
8.
Yan, Tao, Jianzhong Lu, Lanlan Li, et al.. (2024). Raltitrexed induces apoptosis through activating ROS-mediated ER stress by impeding HSPA8 expression in prostate cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1871(3). 119684–119684. 6 indexed citations
9.
Ma, Gui, Bin Zhang, Shengjun Fu, et al.. (2023). Formin-related protein 1 facilitates proliferation and aggressive phenotype of clear cell renal cell carcinoma through MAPK/MMP2 pathway. Molecular and Cellular Probes. 71. 101921–101921. 1 indexed citations
10.
Chen, Siyu, et al.. (2022). The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. Translational Oncology. 20. 101375–101375. 33 indexed citations
11.
Wang, Zirui, Yujiao Wang, Lanlan Li, et al.. (2021). Immune Cell Landscape in Gastric Cancer. BioMed Research International. 2021(1). 1930706–1930706. 15 indexed citations
12.
Ma, Gui, Zirui Wang, Junyao Liu, et al.. (2021). Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma. Journal of Cancer. 12(21). 6563–6575. 7 indexed citations
13.
Dong, Yan, Hong Zhao, Jiangwei Man, Shengjun Fu, & Li Yang. (2021). MMP-9-mediated regulation of hypoxia-reperfusion injury-related neutrophil inflammation in an in vitro proximal tubular cell model. Figshare. 5 indexed citations
14.
Li, Shuwen, Fang Wang, Shengjun Fu, et al.. (2017). Synergistic effect of bladder cancer-specific oncolytic adenovirus in combination with chemotherapy. Oncology Letters. 14(2). 2081–2088. 11 indexed citations
15.
16.
Zhang, Su, You Luo, Cheng Wang, et al.. (2016). Open surgery versus retroperitoneal laparoscopic nephrectomy for renal tuberculosis: a retrospective study of 120 patients. PeerJ. 4. e2708–e2708. 11 indexed citations
17.
Luo, You, et al.. (2015). Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors. Medicine. 94(40). e1670–e1670. 50 indexed citations
18.
Luo, You, et al.. (2015). Kidney-sparing Management Versus Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Systematic Review and Meta-analysis. Asian Pacific Journal of Cancer Prevention. 16(14). 5907–5912. 9 indexed citations
19.
20.
Wang, Li, et al.. (2014). Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro. Tumor Biology. 35(11). 10879–10890. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Qian Breakdown of academic impact, for papers by Dongdong Lin Breakdown of academic impact, for papers by Jianrong Guo Breakdown of academic impact, for papers by Shengbin Dai Breakdown of academic impact, for papers by Tung‐Cheng Chang Breakdown of academic impact, for papers by Zhi Zheng Breakdown of academic impact, for papers by Sakkarn Sangkhamanon Breakdown of academic impact, for papers by An-Kui Yang Breakdown of academic impact, for papers by Jingjing Shao
Rankless by CCL
2026